Clinical Trial

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label，phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2025-08-06
Trial Details
NCT Number NCT06826430
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions Autoimmune Thrombocytopenia
Enrollment 12 participants
Start Date 2025-03-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-07